Financial Health Snapshot
What do Moderna latest financial health metrics show?
Mixed. The strongest factor is $75B in cash and investments, while the main concern is heavy losses and weak cash conversion.
For Q1 2026, the verdict blends growth, profitability, cash generation, balance-sheet capacity, and capital efficiency. Moderna’s latest numbers show a company with meaningful liquidity but still a strained earnings base, so the balance sheet matters as much as sales momentum, including Exploring Moderna, Inc. (MRNA) Investor Profile: Who's Buying and Why?.
Moderna’s latest revenue signal needs the deepest analysis first because Q1 2026 total revenue was $389M versus $108M in Q1 2025, yet FMP 2026-03-31 Revenue Growth was -4263%, showing how seasonal volatility and period sensitivity can distort the picture; 2026 revenue guidance still targets up to 10% growth over 2025 levels, but operating income was -$139B and net income was -$134B.
Revenue Quality
Is Moderna revenue growth producing quality earnings?
Weak. Revenue rebounded sharply in Q1 2026, but the earnings line did not confirm it: operating income, net income, and diluted EPS stayed deeply negative, showing that sales momentum has not yet translated into durable profit.
Growth quantity is improving, but growth quality still looks fragile. Investors compare revenue durability with operating income, net income, and EPS across compatible annual periods to see whether sales create real earnings power, not just temporary revenue spikes. That matters even more for Moderna, Inc.; its Mission Statement, Vision, & Core Values (2026) of Moderna, Inc. (MRNA) sit behind a business model that still depends heavily on vaccine demand and execution.
| Measure | Latest Period | Previous Period | Quality Test | Investor Meaning |
|---|---|---|---|---|
| Revenue | $389M, 260% increase, Q1 2026 | $108M, Q1 2025 | Clearly price- and volume-driven from international COVID-19 vaccine sales | Shows strong rebound, but the source still looks tied to a narrow demand stream |
| Operating Income | -$139B, 2026-03-31 | -$85700M, 2025-12-31 | Grew differently from revenue and stayed loss-making | Revenue did not convert into operating leverage |
| Net Income | -$134B, 2026-03-31 | -$82600M, 2025-12-31 | Negative earnings persisted, with no verified operating or tax rebound | Final earnings still do not confirm the sales improvement |
| Diluted EPS | -$340, 2026-03-31 | -$211, 2025-12-31 | Per-share results weakened | Shareholders did not receive earnings support from the higher revenue base |
How durable is Moderna revenue?
The strongest durability signal is international COVID-19 vaccine sales supported by government partnerships in the UK, Canada, and Australia. The biggest limit is visibility: seasonal endemic demand and a difficult U.S. retail vaccine market still make revenue uneven.
- Demand Quality: Revenue is still tied to recurring but seasonal COVID demand, so visibility is better than a one-time sale but not stable enough for high confidence.
- Pricing and Volume: The supplied data shows growth from international COVID-19 vaccine sales, but the split between price, volume, and mix is not provided.
- Diversification: Government partnerships in the UK, Canada, and Australia help, but revenue remains concentrated in a narrow vaccine category.
That makes profitability and cash conversion the next test.
Losses and Cash
How do losses and cash flow affect Moderna, Inc. margin quality?
Moderna, Inc. showed weak margin quality in Q1 2026, with gross profit, operating income, and net income all negative. Operating cash flow and free cash flow also moved sharply worse, so cash generation did not confirm reported earnings.
Gross profit, operating income, and net income all point to pressure on the profit stack, while operating cash flow shows whether those losses are backed by real cash generation. For Moderna, Inc., the latest numbers also need to be read alongside capital expenditure and a large litigation settlement charge, because those items can distort net income and free cash flow differently. Exploring Moderna, Inc. (MRNA) Investor Profile: Who's Buying and Why?
| Measure | Latest Period | Previous Period | Verified Driver | Investor Meaning |
|---|---|---|---|---|
| Gross Margin | Q1 2026: gross profit was -$56600M | Not provided | Weak product economics were reflected in negative gross profit; no earlier compatible gross margin was supplied. | Product economics were under severe pressure in the latest period. |
| Operating Margin | Q1 2026: operating income was -$139B | Not provided | High R&D spending, including $64900M in Q1 2026, kept operating results deeply negative. | Scale has not yet translated into operating efficiency. |
| Net Margin | Q1 2026: net income was -$134B | Not provided | The GAAP net loss included a $09B non-recurring litigation settlement charge. | Final profitability was weaker than operating results because of the settlement drag. |
| Operating Cash Flow | FMP 2026-03-31: Operating Cash Flow Growth was -16625% | Previous comparable value not supplied | Direction was far weaker than reported earnings, with cash conversion pressure implied by the growth rate. | Accounting earnings were not converting into operating cash. |
| Free Cash Flow | FMP 2026-03-31: Free Cash Flow Growth was -17588% | Previous comparable value not supplied | Capex discipline is suggested by $02B–$03B in 2026 capital expenditures. | Reinvestment needs look controlled, but cash remaining for financing is still under pressure. |
What most affects Moderna, Inc. cash conversion?
The biggest driver appears to be heavy R&D spending, with the Q1 2026 settlement charge also worsening the cash and earnings picture. The large negative cash flow growth shows conversion remains weak.
- Main Driver: Large R&D outlays, plus the litigation settlement charge, look structural in the near term rather than temporary.
- Evidence Gap: The supplied data does not show working-capital detail or a full cash bridge.
- Metric to Monitor: Track operating cash flow and R&D as a share of revenue.
Liquidity Strength
Can Moderna, Inc. balance sheet support its obligations and investment needs?
Strong. Moderna, Inc. has a large liquidity buffer and low near-term funding pressure, with the main protection coming from cash and short-term investments and the main concern being cash use, the Moderna, Inc. (MRNA): History, Ownership, Mission, How It Works & Makes Money profile, and upcoming legal payments.
Cash alone is not enough, so the real test is working capital, asset quality, debt service, solvency, liquidity, and refinancing together. Moderna, Inc. reported strong current assets, but investors should still watch how much cash is consumed by operations, settlement payments, and any refinancing needs tied to debt and credit facilities.
| Area | Latest Evidence | Assessment | Investor Meaning |
|---|---|---|---|
| Cash and Working Capital | Cash and Cash Equivalents were $191B, Short Term Investments were $330B, Cash and Short Term Investments were $521B, and Total Current Assets were $577B. | Strong | Near-term obligations look covered without forcing asset sales or cutting investment sharply. |
| Total and Net Debt | FMP Total Debt was $130B at 2026-03-31, and Short Term Debt was $5000M. | Mixed | Debt is manageable against liquidity, but leverage still reduces flexibility if cash flow weakens. |
| Debt Service and Refinancing | Moderna, Inc. closed a $15B five-year term loan facility with Ares Management Credit Funds and had a $06B draw from a new credit facility included in Cash and Investments at December 31, 2025. | Strong | Credit access supports debt service and refinancing, even if capital needs rise. |
| Asset Quality | Total Assets were $1149B, while company-reported Cash and Investments were $75B at March 31, 2026, down from $81B as of December 31, 2025. | Mixed | Large assets help, but the cash decline shows the need to track burn rate and asset mix closely. |
| Liabilities and Equity | Total liabilities and shareholders' equity were not fully provided, but liabilities are implied by the $130B debt load and ongoing settlement obligations. | Mixed | The capital base appears adequate, but legal and financing claims can still pressure equity. |
Which balance-sheet risk matters most for Moderna, Inc.?
Legal and cash-use risk matters most. The $950M upfront payment due July 08, 2026 and the $13B contingent amount tied to a US appellate ruling are the clearest pressures on liquidity.
- Current Exposure: Cash and Short Term Investments were $521B, but cash and investments fell to $75B from $81B.
- Protection: The strongest buffer is the $521B combined cash and short-term investment position.
- Warning Signal: Monitor whether legal payments, debt, or operating losses keep shrinking cash faster than expected.
Capital Efficiency
Is Moderna, Inc. using capital efficiently while reinvesting heavily?
Moderna, Inc. looks Mixed on capital efficiency. Internal cash appears sufficient for current reinvestment needs, but returns are still pressured by losses, heavy R&D, and manufacturing buildout.
Return quality has to be read alongside leverage, asset intensity, capital expenditure, working capital, and any need for outside funding. For Moderna, Inc., the key question is not just whether capital is being spent, but whether that spending is building future products and capacity faster than it is consuming cash.
| Capital Measure | Latest Evidence | Quality Test | Investor Meaning |
|---|---|---|---|
| ROIC | Unavailable in the supplied data. | Operating margins are still under pressure, so the result cannot be confirmed as strong from the available figures. | Invested capital does not yet show clear operating value creation from the provided information. |
| ROE and ROA | Unavailable in the supplied data. | Negative earnings weaken ROE quality, while a capital-heavy base can also drag ROA. | Shareholder returns look more leverage-sensitive than efficiency-driven, and leverage should not be treated as a strength by itself. |
| Maintenance and Growth Investment | FY2025 Research and Development Expenses were $31B, down 31% from $45B in 2024, and projected 2026 Research and Development Expenses are $30B. Reinvestment also includes Norwood onshoring of Drug Product manufacturing, the Moderna Innovation and Technology Centre in Oxfordshire, and the Laval facility in Canada. | The spending mix shows continued growth investment, but the lower 2026 plan suggests more discipline than pure expansion. | Capital is being used to sustain platform development, expand manufacturing control, and support oncology and rare disease portfolios. |
| Internal Funding Capacity | Capital efficiency remains Mixed because internal cash supports investment, and 2026 Capital Expenditures of $0.2B–$0.3B show a more disciplined plan. | Investment appears internally funded for now, even though returns remain loss-making. | Lower capex helps preserve flexibility, limits dilution risk, and reduces reliance on external capital. |
Are Moderna, Inc.'s returns on capital sustainable?
Sustainability is not yet proven. The strongest support is disciplined funding and a narrower 2026 spending plan, while continued losses or a larger-than-planned reinvestment cycle would weaken returns.
- Operating Source: Lower R&D intensity and a shift toward oncology and rare disease portfolios support future mix.
- Funding Requirement: The largest verified need is continued R&D and manufacturing investment across Norwood, Oxfordshire, and Laval.
- Durability Test: Returns weaken if operating losses persist while ROIC remains unavailable and cash burn rises faster than planned capex.
If you’re using this topic for a paper or case study, a structured SWOT Analysis, PESTLE Analysis, or Business Model Canvas can help organize Moderna, Inc.'s capital allocation, key resources, and funding structure. For a deeper read, Moderna, Inc. (MRNA): History, Ownership, Mission, How It Works & Makes Money gives useful context on how the business model supports reinvestment.
Financial resilience
How resilient is Moderna, Inc. when revenue swings, losses widen, and legal cash demands rise?
Moderna, Inc. looks Mixed. The main buffer is $75B in cash and investments, plus a $15B five-year term loan facility. The most important verified warning sign is the $225B global settlement risk, including a $950M upfront payment due July 08, 2026 and $13B contingent on the appellate outcome.
Moderna, Inc. still has liquidity to absorb stress, but resilience depends on vaccine cash generation and disciplined spending. FY2025 revenue fell to $19B from fiscal 2024, and Q1 2026 showed weak profitability. For background on the business model, see Moderna, Inc. (MRNA): History, Ownership, Mission, How It Works & Makes Money.
| Pressure | Financial Effect | Existing Protection | Warning Signal |
|---|---|---|---|
| Revenue or Margin Pressure | Lower sales reduce operating leverage, widen losses, and limit cash generation and debt capacity; FY2025 revenue of $19B was down 40% compared with fiscal 2024, and Q1 2026 demand depended on international COVID-19 vaccine sales. | Seasonal vaccine demand, international sales, and cost cuts that exceeded initial 2025 targets. | Further revenue decline, weaker margins, or negative operating cash flow. |
| Working-Capital or Investment Pressure | Settlement payments, R&D, and expansion can absorb cash even when the business still funds operations internally. | $75B in cash and investments, plus partnerships with governments in the UK, Canada, and Australia. | Cash and investments falling faster than seasonal vaccine collections after settlement payments. |
| Interest or Refinancing Pressure | The $15B term loan facility improves flexibility, but legal outflows and losses can still tighten financing headroom and free cash flow. | Large cash reserves and access to the five-year term loan facility. | Rising debt use, higher interest burden, or reduced liquidity after the $950M payment date. |
Which financial warning signs should investors monitor at Moderna, Inc.?
The two strongest signals are settlement-linked cash depletion and continued revenue decline. Q1 2026 loss pressure is confirmed; the bigger future risk is whether vaccine cash collections can offset the $950M payment and the larger contingent liability.
Settlement cash drain
The $225B global settlement creates the clearest cash risk, starting with the $950M upfront payment due July 08, 2026. Moderna, Inc. can soften the hit with $75B in cash and investments, but investors should watch post-payment liquidity.
Revenue and margin slippage
FY2025 revenue of $19B was down 40% versus fiscal 2024, and Q1 2026 demand leaned on international COVID-19 vaccine sales. That raises pressure on operating leverage, so the next check is whether revenue and margins stabilize.
Persistent loss profile
Q1 2026 GAAP Net Loss of $13B and GAAP EPS of -$340 show the earnings base is still weak. Cost cuts helped, but investors should monitor whether losses narrow or remain too large for comfort.
Financial Health Score
What is Moderna financial health score for investors?
Moderna gets a Mixed overall rating. The strongest factor is balance sheet liquidity, while the weakest is profitability. The most important investment condition is whether cash-rich funding can bridge losses until revenue visibility and cost discipline improve. For mission context, see Mission Statement, Vision, & Core Values (2026) of Moderna, Inc. (MRNA).
| Financial Factor | Rating | Evidence and Investor Meaning |
|---|---|---|
| Revenue and Earnings Quality | Mixed | Q1 2026 revenue rose versus Q1 2025, but FY2025 revenue fell and earnings remain negative, so growth is not yet durable or per-share earnings driven. |
| Profitability and Cash | Weak | Q1 2026 Gross Profit was -$56600M, Operating Income was -$139B, and Net Income was -$134B, with negative cash-flow growth signals and no current profit cushion. |
| Balance Sheet and Liquidity | Strong | Cash and Investments were $75B, and funding access includes the Ares term loan, giving Moderna meaningful liquidity and debt service flexibility. |
| Capital Efficiency | Mixed | R&D and manufacturing spending support the pipeline, but current returns are loss-making, so reinvestment is high and near-term capital efficiency is limited. |
| Financial Resilience | Mixed | Liquidity buffers are strong, but revenue volatility and settlement cash needs remain pressure points that could weigh on flexibility if losses persist. |
- What Supports the Thesis: $75B in Cash and Investments plus access to the Ares term loan give Moderna time to fund the transition.
- What Challenges the Thesis: Negative profitability and volatile revenue leave investors waiting for clear improvement in cash flow and earnings quality.
- What to Monitor: Cash and Investments; GAAP Net Loss; 2026 revenue versus guidance targeting up to 10% growth over 2025 levels.
That mix matters for forecasts, scenarios, and valuation because Moderna’s cash runway can support multiple outcomes, but the valuation case still depends on whether losses narrow on schedule.
FAQ
What Do Investors Ask About 's Financial Health?
Investors most often ask about the company's revenue quality, profitability, cash generation, debt, liquidity, capital efficiency, and ability to withstand financial pressure.
What drove Moderna quarterly net loss in 2026?
Q1 2026 GAAP Net Loss was $13B and included a $09B non-recurring litigation settlement charge The loss also reflected weak gross profit, high R&D spending, and operating expenses above quarterly revenue
How does seasonal vaccine demand affect cash flow?
Seasonal demand can make revenue and collections uneven across quarters Moderna reported Q1 2026 revenue growth from international COVID-19 vaccine sales, but FY2025 revenue fell as COVID-19 vaccines moved into a seasonal endemic market
What does the Ares term loan mean for liquidity?
The $15B five-year term loan facility with Ares Management Credit Funds strengthens non-dilutive capital access It supports liquidity while Moderna funds operations, R&D, manufacturing changes, and legal settlement obligations
Which cost cuts matter most for Moderna runway?
The most relevant cuts are the $22B annual operating expense reduction, workforce reductions, R&D prioritization, and exit from eight contract manufacturing organizations since 2022 These actions support runway by lowering recurring cash needs
Are Moderna returns strong despite large cash reserves?
Returns are not yet strong because the company remains loss-making Cash reserves support reinvestment, but capital efficiency depends on whether R&D, manufacturing investments, and new product approvals improve revenue durability and cash conversion